First-ever licencing deal struck for cancer drug

Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer drug.


Actions against physician licenses due to substance use down

While actions against physician licenses related to substance use have declined, they remain markedly higher than actions related to physical health, according to a research letter published in the June 3 issue of JAMA Health ...

page 1 from 7